Bluefin Biomedicine
Initial Transaction Details
Transaction Date
July 2025
Purpose of Financing
Venture
Stage of Company
Mid Stage
Structure of Financing
Equity
Bluefin Biomedicine is a privately held, clinical-stage biotechnology company advancing first-in-class antibody medicines anchored in human biology. Bluefin's integrated discovery platform combines proteomics-powered antigen identification with next-generation antibody engineering to resolve target expression within complex human tissues.
Website